{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:28:57Z","timestamp":1787218137929,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100024886","name":"Friedrich-Loeffler-Institut, Bundesforschungsinstitut f\u00fcr Tiergesundheit","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024886","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adjuvants function as an enhancer and activator of the immune response and can be of pivotal importance for the efficacy of vaccines. AS01, which is a liposome formulation spiked with the saponin derivate QS-21 and the detoxified lipopolysaccharide MPL-A, and AS03, which is a squalene-based oil in water emulsion that contains antioxidant tocopherol, are modern, highly potent adjuvants that became integral to innovative vaccines. In the current study, guinea pigs \u2013a well-established small animal model for human influenza-infections\u2013 were subcutaneously vaccinated with an influenza H5N1-antigen formulated with AS01, AS03, aluminium hydroxide or left unformulated. The induction of T- and B cells specific for the influenza antigen was assessed in dependence of the antigen formulation. H5N1-specific T cell responses were observed with all adjuvant formulations, but after six months were highest in the AS01- and AS03-immunized groups. The influenza specific antibody titres were highest in AS03-vaccinated guinea pigs. Importantly, AS03- and AS01-formulated influenza antigen also induced crossreactive antibodies inhibiting related H5N3- but not a distant H5N8-influenza strain. At the same time, it was observed that animals, which received the egg-produced H5N1 split antigen in combination with AS03, mounted xenoreactive, opsonizing antibodies that bound to chicken fibroblasts. No reactivity was observed to human fibroblasts. In summary, our results confirm the superior adjuvanticity of AS03 and of AS01 as compared to conventional alum or non-adjuvanted formulations. The presence of xenoreactive antibodies after AS03 vaccination was an unexpected observation. Further investigations will be required to appreciate the significance and identify the mechanisms of this findings.<\/jats:p>","DOI":"10.1038\/s41598-026-65812-x","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:04:57Z","timestamp":1787216697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the adjuvant effect of AS01, AS03 and alum on the immune response to GMP-grade H5N1 antigen in guinea pigs"],"prefix":"10.1038","volume":"16","author":[{"given":"Emmelie","family":"Eckhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sehl-Ewert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Harder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Teifke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ger","family":"van Zandbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-8568","authenticated-orcid":false,"given":"Max","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"65812_CR1","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","volume":"20","author":"B Pulendran","year":"2021","unstructured":"Pulendran, B., O\u2019Hagan, D. T. & P, S. A. & Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 20, 454\u2013475. https:\/\/doi.org\/10.1038\/s41573-021-00163-y (2021).","journal-title":"Nat. Rev. Drug Discov"},{"key":"65812_CR2","doi-asserted-by":"publisher","first-page":"6597","DOI":"10.1016\/j.vaccine.2010.07.056","volume":"28","author":"M de Veer","year":"2010","unstructured":"de Veer, M., Kemp, J., Chatelier, J., Elhay, M. J. & Meeusen, E. N. The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. Vaccine 28, 6597\u20136602. https:\/\/doi.org\/10.1016\/j.vaccine.2010.07.056 (2010).","journal-title":"Vaccine"},{"key":"65812_CR3","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature06939","volume":"453","author":"SC Eisenbarth","year":"2008","unstructured":"Eisenbarth, S. C., Colegio, O. R., O\u2019Connor, W., Sutterwala, F. S. & Flavell, R. A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453, 1122\u20131126. https:\/\/doi.org\/10.1038\/nature06939 (2008).","journal-title":"Nature"},{"key":"65812_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coi.2017.07.010","volume":"47","author":"DT O\u2019Hagan","year":"2017","unstructured":"O\u2019Hagan, D. T., Friedland, L. R., Hanon, E. & Didierlaurent, A. M. Towards an evidence based approach for the development of adjuvanted vaccines. Curr. Opin. Immunol. 47, 93\u2013102. https:\/\/doi.org\/10.1016\/j.coi.2017.07.010 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"65812_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","volume":"39","author":"G Del Giudice","year":"2018","unstructured":"Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. Semin Immunol. 39, 14\u201321. https:\/\/doi.org\/10.1016\/j.smim.2018.05.001 (2018).","journal-title":"Semin Immunol."},{"key":"65812_CR6","unstructured":"EMA. European Public Assessment Report\u2014Pandemrix. Report No. EMA\/684025\/2012 42 (European Medicines Agency, 2009)."},{"key":"65812_CR7","unstructured":"EMA. European Public Assessment Report\u2014Pumarix. Report No. EMA\/760601\/2010 3 (European Medicines Agency, 2011)."},{"key":"65812_CR8","unstructured":"EMA. European Public Assessment Report\u2014Prepandrix. Report No. EMA\/774844\/2012 3 (European Medicines Agency, 2009)."},{"key":"65812_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1473-3099(21)00764-7","volume":"22","author":"S Sridhar","year":"2022","unstructured":"Sridhar, S. et al. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: Interim findings from a phase 2, randomised, dose-finding, multicentre study. Lancet Infect. Dis. 22, 636\u2013648. https:\/\/doi.org\/10.1016\/S1473-3099(21)00764-7 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"65812_CR10","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1016\/j.vaccine.2022.05.046","volume":"40","author":"C Dube","year":"2022","unstructured":"Dube, C. et al. Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-adjuvanted recombinant plant-derived virus-like particle vaccines. Vaccine 40, 4017\u20134025. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.046 (2022).","journal-title":"Vaccine"},{"key":"65812_CR11","unstructured":"Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19), (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05007951"},{"key":"65812_CR12","unstructured":"Press Release: EMA\u2019s CHMP started evaluating the application for a conditional marketing authorisation of Sanofi Pasteur\u2019s COVID-19 vaccine, Vidprevtyn, (2022). https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-latest-updates"},{"key":"65812_CR13","unstructured":"EMA. Vidprevtyn Beta\u2014EPAR Medicine Overview. Report No. EMA\/872778\/2022 4 (European Medicines Agency, Amsterdam)."},{"key":"65812_CR14","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","volume":"28","author":"W Keitel","year":"2010","unstructured":"Keitel, W. et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1\/2 clinical trial. Vaccine 28, 840\u2013848. https:\/\/doi.org\/10.1016\/j.vaccine.2009.10.019 (2010).","journal-title":"Vaccine"},{"key":"65812_CR15","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","volume":"37","author":"C Cohet","year":"2019","unstructured":"Cohet, C. et al. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. Vaccine 37, 3006\u20133021. https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.048 (2019).","journal-title":"Vaccine"},{"key":"65812_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/MCP.0000000000000426","volume":"23","author":"M Bonvalet","year":"2017","unstructured":"Bonvalet, M., Ollila, H. M., Ambati, A. & Mignot, E. Autoimmunity in narcolepsy. Curr. Opin. Pulm Med. 23, 522\u2013529. https:\/\/doi.org\/10.1097\/MCP.0000000000000426 (2017).","journal-title":"Curr. Opin. Pulm Med."},{"key":"65812_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/ana.22587","volume":"70","author":"F Han","year":"2011","unstructured":"Han, F. et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70, 410\u2013417. https:\/\/doi.org\/10.1002\/ana.22587 (2011).","journal-title":"Ann. Neurol."},{"key":"65812_CR18","doi-asserted-by":"publisher","unstructured":"Rossmann, L. et al. Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response. Proc. Natl. Acad. Sci. U S A  https:\/\/doi.org\/10.1073\/pnas.2103651118 (2021).","DOI":"10.1073\/pnas.2103651118"},{"key":"65812_CR19","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00705-018-4023-3","volume":"164","author":"VA Evseenko","year":"2019","unstructured":"Evseenko, V. A. et al. Intranasal immunization of guinea pig with trivalent influenza antigen adjuvanted by Cyclamen europaeum tubers extract. Arch. Virol. 164, 243\u2013247. https:\/\/doi.org\/10.1007\/s00705-018-4023-3 (2019).","journal-title":"Arch. Virol."},{"key":"65812_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/978-1-4939-8678-1_20","volume":"1836","author":"JD Hemmink","year":"2018","unstructured":"Hemmink, J. D., Whittaker, C. J. & Shelton, H. A. Animal models in influenza research. Methods Mol. Biol. 1836, 401\u2013430. https:\/\/doi.org\/10.1007\/978-1-4939-8678-1_20 (2018).","journal-title":"Methods Mol. Biol."},{"key":"65812_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.vaccine.2016.11.052","volume":"35","author":"K Schultheis","year":"2017","unstructured":"Schultheis, K. et al. Characterization of guinea pig T cell responses elicited after EP-assisted delivery of DNA vaccines to the skin. Vaccine 35, 61\u201370. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.052 (2017).","journal-title":"Vaccine"},{"key":"65812_CR22","doi-asserted-by":"crossref","unstructured":"Baxter, V. K. & Griffin, D. E. Viral Pathogenesis 125\u2013138 (Elsevier, 2016).","DOI":"10.1016\/B978-0-12-800964-2.00010-0"},{"key":"65812_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.tube.2009.08.004","volume":"89","author":"A Williams","year":"2009","unstructured":"Williams, A., Hall, Y. & Orme, I. M. Evaluation of new vaccines for tuberculosis in the guinea pig model. Tuberculosis (Edinb). 89, 389\u2013397 (2009).","journal-title":"Tuberculosis (Edinb)"},{"key":"65812_CR24","doi-asserted-by":"publisher","first-page":"18613","DOI":"10.1038\/s41598-023-45898-3","volume":"13","author":"E Eckhardt","year":"2023","unstructured":"Eckhardt, E. et al. Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge. Sci. Rep. 13, 18613. https:\/\/doi.org\/10.1038\/s41598-023-45898-3 (2023).","journal-title":"Sci. Rep."},{"key":"65812_CR25","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/j.vaccine.2015.12.057","volume":"34","author":"S Hopf","year":"2016","unstructured":"Hopf, S., Garner-Spitzer, E., Hofer, M., Kundi, M. & Wiedermann, U. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine. Vaccine 34, 2027\u20132034. https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.057 (2016).","journal-title":"Vaccine"},{"key":"65812_CR26","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.vaccine.2014.12.024","volume":"33","author":"J Diez-Domingo","year":"2015","unstructured":"Diez-Domingo, J. et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged >\/=50 years: A randomised non-inferiority clinical trial. Vaccine 33, 789\u2013795. https:\/\/doi.org\/10.1016\/j.vaccine.2014.12.024 (2015).","journal-title":"Vaccine"},{"key":"65812_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1741-7015-7-16","volume":"7","author":"Y Gillet","year":"2009","unstructured":"Gillet, Y., Habermehl, P., Thomas, S., Eymin, C. & Fiquet, A. Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro) and a varicella vaccine (VARIVAX) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial. BMC Med. 7, 16. https:\/\/doi.org\/10.1186\/1741-7015-7-16 (2009).","journal-title":"BMC Med."},{"key":"65812_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1086\/317553","volume":"32","author":"FL Ruben","year":"2001","unstructured":"Ruben, F. L. et al. Choosing a route of administration for quadrivalent meningococcal polysaccharide vaccine: Intramuscular versus subcutaneous. Clin. Infect. Dis. 32, 170\u2013172. https:\/\/doi.org\/10.1086\/317553 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"65812_CR29","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1542\/peds.88.3.604","volume":"88","author":"PH Dennehy","year":"1991","unstructured":"Dennehy, P. H., Reisinger, K. S., Blatter, M. M. & Veloudis, B. A. Immunogenicity of subcutaneous versus intramuscular Oka\/Merck varicella vaccination in healthy children. Pediatrics 88, 604\u2013607 (1991).","journal-title":"Pediatrics"},{"key":"65812_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jviromet.2011.01.006","volume":"173","author":"A Postel","year":"2011","unstructured":"Postel, A. et al. Broad spectrum reactivity versus subtype specificity-trade-offs in serodiagnosis of influenza A virus infections by competitive ELISA. J. Virol. Methods. 173, 49\u201359. https:\/\/doi.org\/10.1016\/j.jviromet.2011.01.006 (2011).","journal-title":"J. Virol. Methods"},{"key":"65812_CR31","doi-asserted-by":"crossref","unstructured":"Bastian, M., Holsteg, M., Hanke-Robinson, H., Duchow, K. & Cussler, K. Bovine neonatal pancytopenia: Is this alloimmune syndrome caused by vaccine-induced alloreactive antibodies? Vaccine 29, 5267\u20135275 (2011).","DOI":"10.1016\/j.vaccine.2011.05.012"},{"key":"65812_CR32","doi-asserted-by":"publisher","first-page":"e109239","DOI":"10.1371\/journal.pone.0109239","volume":"9","author":"R Kasonta","year":"2014","unstructured":"Kasonta, R. et al. Colostrum from cows immunized with a vaccine associated with Bovine Neonatal Pancytopenia contains allo-antibodies that cross-react with human MHC-I molecules. PLoS One. 9, e109239 (2014).","journal-title":"PLoS One"},{"key":"65812_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/sqb.1989.054.01.003","volume":"54 Pt 1","author":"CA Janeway","year":"1989","unstructured":"Janeway, C. A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp. Quant. Biol. 54 Pt 1, 1\u201313. https:\/\/doi.org\/10.1101\/sqb.1989.054.01.003 (1989).","journal-title":"Cold Spring Harb Symp. Quant. Biol."},{"key":"65812_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/vim.2017.0049","volume":"31","author":"Y Burakova","year":"2018","unstructured":"Burakova, Y., Madera, R., McVey, S., Schlup, J. R. & Shi, J. Adjuvants for animal vaccines. Viral Immunol. 31, 11\u201322. https:\/\/doi.org\/10.1089\/vim.2017.0049 (2018).","journal-title":"Viral Immunol."},{"key":"65812_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41541-021-00337-0","volume":"6","author":"S Budroni","year":"2021","unstructured":"Budroni, S. et al. Antibody avidity, persistence, and response to antigen recall: Comparison of vaccine adjuvants. NPJ Vaccines. 6, 78. https:\/\/doi.org\/10.1038\/s41541-021-00337-0 (2021).","journal-title":"NPJ Vaccines"},{"key":"65812_CR36","doi-asserted-by":"publisher","first-page":"ofu091","DOI":"10.1093\/ofid\/ofu091","volume":"1","author":"WH Chen","year":"2014","unstructured":"Chen, W. H. et al. Safety, reactogenicity, and immunogenicity of inactivated monovalent influenza A(H5N1) virus vaccine administered with or without AS03 adjuvant. Open. Forum Infect. Dis. 1, ofu091. https:\/\/doi.org\/10.1093\/ofid\/ofu091 (2014).","journal-title":"Open. Forum Infect. Dis."},{"key":"65812_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s10875-010-9490-6","volume":"31","author":"P Moris","year":"2011","unstructured":"Moris, P. et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J. Clin. Immunol. 31, 443\u2013454. https:\/\/doi.org\/10.1007\/s10875-010-9490-6 (2011).","journal-title":"J. Clin. Immunol."},{"key":"65812_CR38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.vaccine.2020.11.041","volume":"39","author":"A Haveri","year":"2021","unstructured":"Haveri, A., Ikonen, N., Savolainen-Kopra, C. & Julkunen, I. Long-lasting heterologous antibody responses after sequential vaccination with A\/Indonesia\/5\/2005 and A\/Vietnam\/1203\/2004 pre-pandemic influenza A(H5N1) virus vaccines. Vaccine 39, 402\u2013411. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.041 (2021).","journal-title":"Vaccine"},{"key":"65812_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41541-018-0076-2","volume":"3","author":"S Khurana","year":"2018","unstructured":"Khurana, S. et al. AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization. NPJ Vaccines. 3, 40. https:\/\/doi.org\/10.1038\/s41541-018-0076-2 (2018).","journal-title":"NPJ Vaccines"},{"key":"65812_CR40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2165\/00063030-200822050-00001","volume":"22","author":"NJ Carter","year":"2008","unstructured":"Carter, N. J. & Plosker, G. L. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: A review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22, 279\u2013292. https:\/\/doi.org\/10.2165\/00063030-200822050-00001 (2008).","journal-title":"BioDrugs"},{"key":"65812_CR41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1517\/14712590903066695","volume":"9","author":"G Leroux-Roels","year":"2009","unstructured":"Leroux-Roels, G. & Prepandemic H5N1 influenza vaccine adjuvanted with AS03: A review of the pre-clinical and clinical data. Expert Opin. Biol. Ther. 9, 1057\u20131071. https:\/\/doi.org\/10.1517\/14712590903066695 (2009).","journal-title":"Expert Opin. Biol. Ther."},{"key":"65812_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael, Y. et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat. Med. 19, 465\u2013472. https:\/\/doi.org\/10.1038\/nm.3105 (2013).","journal-title":"Nat. Med."},{"key":"65812_CR43","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.0818-9641.2004.01272.x","volume":"82","author":"N Petrovsky","year":"2004","unstructured":"Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: Current state and future trends. Immunol. Cell. Biol. 82, 488\u2013496. https:\/\/doi.org\/10.1111\/j.0818-9641.2004.01272.x (2004).","journal-title":"Immunol. Cell. Biol."},{"key":"65812_CR44","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.vaccine.2008.02.063","volume":"26","author":"L Bungener","year":"2008","unstructured":"Bungener, L. et al. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26, 2350\u20132359. https:\/\/doi.org\/10.1016\/j.vaccine.2008.02.063 (2008).","journal-title":"Vaccine"},{"key":"65812_CR45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaci.2009.12.015","volume":"125","author":"KH Waibel","year":"2010","unstructured":"Waibel, K. H. & Gomez, R. Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines. J. Allergy Clin. Immunol. 125, 749\u2013751. https:\/\/doi.org\/10.1016\/j.jaci.2009.12.015 (2010). 751 e741.","journal-title":"J. Allergy Clin. Immunol."},{"key":"65812_CR46","unstructured":"Mark, C. Large variations in the ovalbumin content in six European influenza vaccines. Pharmeur Sci Notes 2006, 27\u201329 (2006)."},{"key":"65812_CR47","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/j.1399-3038.2011.01158.x","volume":"22","author":"ME Goldis","year":"2011","unstructured":"Goldis, M. E., Bardina, L., Gimenez, G., Lin, J. & Sampson, H. A. Evaluation of flu vaccines with regard to their egg protein content. Pediatr. Allergy Immunol. 22, 642\u2013643. https:\/\/doi.org\/10.1111\/j.1399-3038.2011.01158.x (2011).","journal-title":"Pediatr. Allergy Immunol."},{"key":"65812_CR48","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.vaccine.2010.01.044","volume":"28","author":"C Miyaki","year":"2010","unstructured":"Miyaki, C. et al. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine 28, 2505\u20132509. https:\/\/doi.org\/10.1016\/j.vaccine.2010.01.044 (2010).","journal-title":"Vaccine"},{"key":"65812_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF01591484","volume":"15","author":"I Chaloupka","year":"1996","unstructured":"Chaloupka, I., Schuler, A., Marschall, M. & Meier-Ewert, H. Comparative analysis of six European influenza vaccines. Eur. J. Clin. Microbiol. Infect. Dis. 15, 121\u2013127. https:\/\/doi.org\/10.1007\/BF01591484 (1996).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"65812_CR50","doi-asserted-by":"publisher","first-page":"e000186","DOI":"10.1136\/bmjopen-2011-000186","volume":"2","author":"BA Forsdahl","year":"2012","unstructured":"Forsdahl, B. A. Reactions of Norwegian children with severe egg allergy to an egg-containing influenza A (H1N1) vaccine: A retrospective audit. BMJ Open. 2, e000186. https:\/\/doi.org\/10.1136\/bmjopen-2011-000186 (2012).","journal-title":"BMJ Open."},{"key":"65812_CR51","first-page":"423","volume":"64","author":"A Friedrich","year":"2009","unstructured":"Friedrich, A. et al. Increase in the incidence of a bleeding disorder in young calves due to bone marrow damage. Tier\u00e4rztl Umschau. 64, 423\u2013431 (2009). (German)","journal-title":"Tier\u00e4rztl Umschau"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65812-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:18:09Z","timestamp":1787217489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-65812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["65812"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-65812-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments were conducted in accordance with European animal welfare legislation and all relevant animal welfare guidelines. The animal trial protocol was approved by the competent authority, the Landesamt f\u00fcr Landwirtschaft, Lebensmittelsicherheit und Fischerei, Mecklenburg-Vorpommern (7221.3-1-010\/20).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26175"}}